TOKENPOST
1 min read
Add as a preferred source on Google

Tarsus Pharmaceuticals Revenue Climbs 63.9% to $194.5 Million in Q3

GAAP earnings per share was -$14.40. Cash, cash equivalents and marketable securities totaled $309.6 million as of Sept. 30.

By John Kim
Published
An eye drop bottle rests beside an ophthalmic examination instrument / TokenPost.ai
An eye drop bottle rests beside an ophthalmic examination instrument / TokenPost.ai

Tarsus Pharmaceuticals' third-quarter revenue was $194.5 million, up 63.9% year over year.

GAAP earnings per share was -$14.40.

Cash, cash equivalents and marketable securities totaled $309.6 million as of Sept. 30.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…